{"address1": "62 Lygon Street", "address2": "Level 3", "city": "Carlton", "state": "VIC", "zip": "3053", "country": "Australia", "phone": "61 3 9824 5254", "fax": "61 3 9822 7735", "website": "https://www.radiopharmtheranostics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting av\u00df6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an av\u00df6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD", "age": 68, "title": "Founder & Executive Chairman", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 202335, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Riccardo  Canevari", "title": "MD, CEO & Director", "fiscalYear": 2024, "totalPay": 981075, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Phillip  Hains", "title": "CFO, Joint Company Secretary & Director", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dimitris  Voliotis M.D.", "age": 61, "title": "Chief Medical Officer", "yearBorn": 1963, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Hitesh  Goel", "title": "Head of Project Management", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nathan  Jong C.A.", "title": "Joint Company Secretary", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.81, "open": 4.95, "dayLow": 4.48, "dayHigh": 5.05, "regularMarketPreviousClose": 4.81, "regularMarketOpen": 4.95, "regularMarketDayLow": 4.48, "regularMarketDayHigh": 5.05, "payoutRatio": 0.0, "beta": 0.887, "volume": 28066, "regularMarketVolume": 28066, "averageVolume": 217665, "averageVolume10days": 41980, "averageDailyVolume10Day": 41980, "bid": 5.42, "ask": 6.08, "bidSize": 1, "askSize": 1, "marketCap": 36410632, "fiftyTwoWeekLow": 3.55, "fiftyTwoWeekHigh": 50.82, "priceToSalesTrailing12Months": 110.12568, "fiftyDayAverage": 5.2194, "twoHundredDayAverage": 5.505329, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 10261391360, "profitMargins": 0.0, "floatShares": 1456608123, "sharesOutstanding": 7779930, "sharesShort": 80872, "sharesShortPriorMonth": 43570, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0104, "heldPercentInsiders": 0.0, "heldPercentInstitutions": 0.0677, "shortRatio": 0.16, "bookValue": 0.024, "priceToBook": 194.99998, "lastFiscalYearEnd": 1719705600, "nextFiscalYearEnd": 1751241600, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -43002732, "trailingEps": -11.72, "enterpriseToRevenue": 31036.064, "enterpriseToEbitda": -311.014, "52WeekChange": -0.7351443, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 4.68, "targetHighPrice": 0.14822097, "targetLowPrice": 0.14822097, "targetMeanPrice": 0.14822097, "targetMedianPrice": 0.14822097, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 36436936, "totalCashPerShare": 0.017, "ebitda": -32993392, "totalDebt": 0, "quickRatio": 3.247, "currentRatio": 3.374, "totalRevenue": 330628, "revenuePerShare": 0.0, "returnOnAssets": -0.28947002, "returnOnEquity": -1.12209, "grossProfits": -21384584, "freeCashflow": -16476223, "operatingCashflow": -33419496, "revenueGrowth": -0.4, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -8.12579, "financialCurrency": "AUD", "symbol": "RADX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1733409000000, "preMarketChange": 0.11000013, "preMarketChangePercent": 2.3404284, "preMarketPrice": 4.81, "marketState": "PRE", "regularMarketChangePercent": -2.7027051, "regularMarketPrice": 4.68, "shortName": "Radiopharm Theranostics Limited", "longName": "Radiopharm Theranostics Limited", "regularMarketChange": -0.13000011, "regularMarketDayRange": "4.48 - 5.05", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 217665, "fiftyTwoWeekLowChange": 1.1299999, "fiftyTwoWeekLowChangePercent": 0.3183098, "fiftyTwoWeekRange": "3.55 - 50.82", "fiftyTwoWeekHighChange": -46.14, "fiftyTwoWeekHighChangePercent": -0.9079103, "fiftyTwoWeekChangePercent": -73.514435, "epsTrailingTwelveMonths": -11.72, "epsCurrentYear": -0.023, "priceEpsCurrentYear": -203.47826, "fiftyDayAverageChange": -0.5394001, "fiftyDayAverageChangePercent": -0.10334523, "twoHundredDayAverageChange": -0.8253293, "twoHundredDayAverageChangePercent": -0.14991462, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-11-27", "corporateActions": [], "preMarketTime": 1743595494, "regularMarketTime": 1743537600, "exchange": "NCM", "messageBoardId": "finmb_1685428878", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Radiopharm Theranostics", "trailingPegRatio": null}